PFE - Leap Therapeutics: 2 Catalysts With Cancer Drug DKN-01 In The 2nd Half Of 2022
- Positive results using DKN-01 plus chemotherapy for the treatment of patients with metastatic castration-resistant prostate cancer were presented at ASCO 2022 medical conference.
- The global prostate cancer market could reach $12 billion by 2025.
- Positive initial results using DKN-01 in both 1st line and 2nd line DKK1-high expression gastric cancer patients were released, Updated data for both expected Q3 and Q4 of 2022 respectively.
- Leap Therapeutics had $103.2 million in cash as of March 31, 2022; It believes that it has enough to fund its operations for at least the next 12 months from the date of the SEC filing of May 13, 2022.
For further details see:
Leap Therapeutics: 2 Catalysts With Cancer Drug DKN-01 In The 2nd Half Of 2022